[No advantage for the overall group of breast cancer patients undergoing adjuvant therapy with zoledronic acid].
MVZ Radioonkologie, Universitätsklinikum Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland. rainer.souchon@med.uni-tuebingen.de
R
R
Souchon